Kiora Q1 FY26 net loss widens to $2.42 million; operating loss widens to $2.51 million

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals, Inc. - Common Stock

KPRX

0.00
  • Kiora Pharmaceuticals posted a net loss of $2.42 million, or $0.58 per share, versus a net loss of $2.19 million, or $0.52 per share, a year earlier.
  • Operating loss widened to $2.51 million from $2.33 million, while interest income fell to $139,338 from $276,633.
  • Cash and short-term investments ended quarter at $13.9 million; management said runway extends into late 2028, supported by expected collaboration reimbursements and $5 million in gross proceeds from a strategic equity investment completed after quarter-end.
  • Phase 2 ABACUS-2 enrollment for KIO-301 was described as very active with close to 50% completed, ongoing or scheduled; Phase 2 KLARITY study of KIO-104 is nearing a pre-defined safety review to support moving to the next dose level.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief on May 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.